Amgen Inc. is a biotechnology company dedicated to discovering, developing, manufacturing, and delivering human therapeutics. It focuses on addressing high unmet medical needs to enhance health outcomes and improve lives. Operating primarily in the human therapeutics segment, Amgen's extensive portfolio includes well-known products such as Aranesp, ENBREL, Prolia, Neulasta, Otezla, and Repatha, among others. These therapies target various conditions, showcasing Amgen's commitment to leveraging its expertise in biotechnology to provide innovative solutions for patients. We show 62 historical shares outstanding datapoints in our AMGN shares outstanding history coverage, used to compute AMGN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AMGN market cap history over the course of time is important for investors
interested in comparing AMGN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AMGN versus a peer is one thing; comparing
AMGN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AMGN can fluctuate over the course of history.
With this page we aim to empower investors researching AMGN by allowing them to research the AMGN market cap history. |
Free AMGN Email Alerts:
Video: The Importance of Market Cap
